Nurix Therapeutics Inc. (NRIX)
NASDAQ · Healthcare
Nurix Therapeutics Inc. EBITDA 2019–2025
Nurix Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Nurix Therapeutics Inc. ebitda for the quarter ending February 28, 2026 was -90.3 M, a 49.22% increase year-over-year.
- Nurix Therapeutics Inc. ebitda for the twelve months ending February 28, 2026 was -235.2 M, a 47.28% increase year-over-year.
- Nurix Therapeutics Inc. annual ebitda for 2025 was -276.9 M, a 35.94% increase from 2024.
- Nurix Therapeutics Inc. annual ebitda for 2024 was -203.7 M, a 38.08% increase from 2023.
- Nurix Therapeutics Inc. annual ebitda for 2023 was -147.5 M, a 17.36% decrease from 2022.
- Nurix Therapeutics Inc. annual ebitda for 2022 was -178.5 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Nurix Therapeutics Inc. EBITDA — FAQ
Nurix Therapeutics Inc. (NRIX) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see NRIX's ebitda history?
The chart and table above show Nurix Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.